IDWeek 2024

IDWeek 2024

Brogan AP, et al.

People with HIV in the US switching to cabotegravir + rilpivirine long-acting (CAB+RPV LA) from oral antiretroviral therapy (ART) have numerous real-world benefits, including high adherence and treatment satisfaction

IDWeek24_P08_538_2024-10-15
Video Player is loading.
Current Time 0:00
Duration 3:36
Loaded: 2.75%
Stream Type LIVE
Remaining Time 3:36
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Navigate to: